| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anorexia Nervosa | 34 | 2023 | 1286 | 6.690 |
Why?
|
| Bone Density | 79 | 2023 | 3469 | 6.510 |
Why?
|
| Vitamin D Deficiency | 40 | 2022 | 1331 | 5.730 |
Why?
|
| Absorptiometry, Photon | 48 | 2023 | 1726 | 4.890 |
Why?
|
| Bone and Bones | 28 | 2021 | 2575 | 3.650 |
Why?
|
| Amenorrhea | 13 | 2023 | 485 | 3.530 |
Why?
|
| Vitamin D | 43 | 2022 | 3211 | 3.330 |
Why?
|
| Dehydroepiandrosterone | 10 | 2019 | 252 | 2.620 |
Why?
|
| Osteoporosis | 23 | 2019 | 1581 | 2.440 |
Why?
|
| Fractures, Bone | 18 | 2022 | 1945 | 2.260 |
Why?
|
| Ergocalciferols | 5 | 2015 | 110 | 2.200 |
Why?
|
| Primary Ovarian Insufficiency | 3 | 2023 | 115 | 1.950 |
Why?
|
| Rickets | 4 | 2022 | 74 | 1.940 |
Why?
|
| Progeria | 6 | 2019 | 185 | 1.760 |
Why?
|
| Adolescent | 146 | 2023 | 85649 | 1.670 |
Why?
|
| Menstrual Cycle | 8 | 2023 | 551 | 1.640 |
Why?
|
| Bone Diseases | 4 | 2017 | 416 | 1.340 |
Why?
|
| Cholecalciferol | 8 | 2022 | 537 | 1.280 |
Why?
|
| Polycystic Ovary Syndrome | 8 | 2007 | 369 | 1.190 |
Why?
|
| Calcium, Dietary | 6 | 2020 | 527 | 1.150 |
Why?
|
| Norethindrone | 4 | 2018 | 59 | 1.120 |
Why?
|
| Gonadotropin-Releasing Hormone | 7 | 2022 | 1185 | 1.120 |
Why?
|
| Diphosphonates | 8 | 2020 | 625 | 1.110 |
Why?
|
| Cystic Fibrosis | 7 | 2021 | 1178 | 1.090 |
Why?
|
| Bone Marrow | 5 | 2022 | 2941 | 1.070 |
Why?
|
| Hormone Replacement Therapy | 5 | 2018 | 744 | 1.030 |
Why?
|
| Adrenal Hyperplasia, Congenital | 4 | 2013 | 98 | 1.030 |
Why?
|
| Inflammatory Bowel Diseases | 7 | 2021 | 2410 | 0.980 |
Why?
|
| Lumbar Vertebrae | 7 | 2022 | 1844 | 0.980 |
Why?
|
| Levonorgestrel | 4 | 2019 | 77 | 0.980 |
Why?
|
| Ethinyl Estradiol | 4 | 2019 | 116 | 0.960 |
Why?
|
| Exocrine Pancreatic Insufficiency | 2 | 2015 | 80 | 0.930 |
Why?
|
| Knee | 3 | 2017 | 274 | 0.910 |
Why?
|
| Spinal Fractures | 7 | 2022 | 698 | 0.900 |
Why?
|
| Child | 84 | 2023 | 77478 | 0.900 |
Why?
|
| Hypogonadism | 3 | 2023 | 798 | 0.900 |
Why?
|
| Puberty | 5 | 2020 | 489 | 0.900 |
Why?
|
| Adolescent Health Services | 3 | 2022 | 215 | 0.900 |
Why?
|
| Vitamins | 8 | 2017 | 1608 | 0.890 |
Why?
|
| Hypothalamic Diseases | 2 | 2017 | 135 | 0.890 |
Why?
|
| Estrogens | 9 | 2023 | 1562 | 0.880 |
Why?
|
| Adolescent Development | 3 | 2020 | 277 | 0.870 |
Why?
|
| Pregnancy in Adolescence | 2 | 2022 | 157 | 0.860 |
Why?
|
| Crohn Disease | 6 | 2022 | 2301 | 0.860 |
Why?
|
| Female | 162 | 2023 | 379592 | 0.850 |
Why?
|
| Parathyroid Hormone | 17 | 2019 | 1801 | 0.850 |
Why?
|
| Medroxyprogesterone | 1 | 2021 | 37 | 0.830 |
Why?
|
| Bone Development | 3 | 2020 | 483 | 0.820 |
Why?
|
| Estrogens, Conjugated (USP) | 4 | 2018 | 275 | 0.790 |
Why?
|
| Humans | 215 | 2023 | 742088 | 0.780 |
Why?
|
| Anthropometry | 9 | 2017 | 1350 | 0.780 |
Why?
|
| Sex Reassignment Surgery | 1 | 2022 | 130 | 0.720 |
Why?
|
| Exercise | 10 | 2017 | 5611 | 0.710 |
Why?
|
| Dietary Supplements | 16 | 2022 | 3294 | 0.700 |
Why?
|
| Pregnancy Rate | 1 | 2022 | 643 | 0.700 |
Why?
|
| Body Composition | 13 | 2023 | 2400 | 0.690 |
Why?
|
| Bone Density Conservation Agents | 6 | 2020 | 774 | 0.670 |
Why?
|
| Calcification, Physiologic | 2 | 2017 | 169 | 0.660 |
Why?
|
| Endometriosis | 5 | 2018 | 834 | 0.660 |
Why?
|
| Adipose Tissue | 7 | 2022 | 3278 | 0.640 |
Why?
|
| Femur Neck | 3 | 2015 | 309 | 0.630 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2018 | 89 | 0.630 |
Why?
|
| Bone Remodeling | 5 | 2011 | 575 | 0.610 |
Why?
|
| Coronavirus | 1 | 2020 | 158 | 0.600 |
Why?
|
| Turner Syndrome | 1 | 2018 | 130 | 0.590 |
Why?
|
| Fractures, Spontaneous | 2 | 2017 | 230 | 0.550 |
Why?
|
| Sexual Maturation | 1 | 2017 | 265 | 0.540 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2014 | 113 | 0.540 |
Why?
|
| Bone Resorption | 5 | 2015 | 722 | 0.540 |
Why?
|
| Leuprolide | 3 | 2018 | 303 | 0.530 |
Why?
|
| Family Planning Services | 2 | 2022 | 258 | 0.510 |
Why?
|
| Forearm | 2 | 2019 | 407 | 0.510 |
Why?
|
| Young Adult | 45 | 2022 | 56350 | 0.510 |
Why?
|
| Ovarian Diseases | 2 | 2020 | 139 | 0.510 |
Why?
|
| Quality of Life | 6 | 2022 | 12730 | 0.500 |
Why?
|
| Fetal Growth Retardation | 1 | 2018 | 570 | 0.490 |
Why?
|
| Menarche | 6 | 2020 | 513 | 0.490 |
Why?
|
| Densitometry | 1 | 2014 | 156 | 0.480 |
Why?
|
| Tibia | 4 | 2019 | 1075 | 0.470 |
Why?
|
| Dehydroepiandrosterone Sulfate | 3 | 2006 | 238 | 0.470 |
Why?
|
| Adiposity | 2 | 2022 | 1806 | 0.470 |
Why?
|
| Double-Blind Method | 17 | 2022 | 12017 | 0.460 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2011 | 162 | 0.450 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2010 | 703 | 0.440 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2013 | 54 | 0.440 |
Why?
|
| Contraception | 2 | 2018 | 356 | 0.440 |
Why?
|
| Adolescent Behavior | 3 | 2018 | 1150 | 0.430 |
Why?
|
| Estrogen Replacement Therapy | 5 | 2015 | 1202 | 0.430 |
Why?
|
| Menstruation | 1 | 2014 | 299 | 0.420 |
Why?
|
| Alkaline Phosphatase | 4 | 2009 | 865 | 0.410 |
Why?
|
| Contraception, Postcoital | 1 | 2011 | 22 | 0.410 |
Why?
|
| Formularies as Topic | 1 | 2012 | 91 | 0.410 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2020 | 2014 | 0.400 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 3 | 2015 | 63 | 0.400 |
Why?
|
| Obesity, Abdominal | 1 | 2014 | 361 | 0.400 |
Why?
|
| Male | 83 | 2023 | 349538 | 0.390 |
Why?
|
| Fractures, Stress | 3 | 2011 | 186 | 0.390 |
Why?
|
| S100 Proteins | 1 | 2012 | 259 | 0.390 |
Why?
|
| Progestins | 2 | 2012 | 303 | 0.390 |
Why?
|
| Calcium | 11 | 2019 | 5753 | 0.390 |
Why?
|
| Nutritional Status | 7 | 2011 | 1606 | 0.380 |
Why?
|
| Malnutrition | 3 | 2014 | 625 | 0.380 |
Why?
|
| Thinness | 1 | 2014 | 479 | 0.380 |
Why?
|
| Hip | 5 | 2014 | 257 | 0.370 |
Why?
|
| Leptin | 4 | 2017 | 1593 | 0.370 |
Why?
|
| Administration, Oral | 6 | 2018 | 3913 | 0.370 |
Why?
|
| Femur | 3 | 2019 | 1297 | 0.370 |
Why?
|
| Calcinosis | 1 | 2019 | 1497 | 0.360 |
Why?
|
| Glucocorticoids | 5 | 2008 | 2107 | 0.360 |
Why?
|
| Child, Preschool | 23 | 2019 | 40955 | 0.360 |
Why?
|
| Contraceptive Agents, Female | 1 | 2011 | 135 | 0.360 |
Why?
|
| Human Growth Hormone | 2 | 2012 | 683 | 0.360 |
Why?
|
| Weight Loss | 3 | 2011 | 2604 | 0.350 |
Why?
|
| Calcitonin | 1 | 2011 | 336 | 0.350 |
Why?
|
| Calcifediol | 4 | 2017 | 166 | 0.350 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2012 | 336 | 0.350 |
Why?
|
| Pseudomonas Infections | 1 | 2014 | 608 | 0.340 |
Why?
|
| Adult | 58 | 2022 | 213712 | 0.340 |
Why?
|
| Infant | 20 | 2019 | 35070 | 0.340 |
Why?
|
| Bone Diseases, Metabolic | 4 | 2021 | 417 | 0.340 |
Why?
|
| Infertility, Female | 1 | 2015 | 784 | 0.340 |
Why?
|
| Urban Population | 3 | 2017 | 2018 | 0.340 |
Why?
|
| Bed Rest | 1 | 2009 | 84 | 0.330 |
Why?
|
| Health | 2 | 2011 | 390 | 0.330 |
Why?
|
| Body Mass Index | 10 | 2022 | 12695 | 0.330 |
Why?
|
| Cranial Irradiation | 1 | 2011 | 401 | 0.330 |
Why?
|
| Pediatrics | 5 | 2020 | 3462 | 0.320 |
Why?
|
| Obesity | 7 | 2022 | 12705 | 0.320 |
Why?
|
| Radius | 2 | 2014 | 422 | 0.320 |
Why?
|
| Environmental Pollutants | 3 | 2023 | 1180 | 0.320 |
Why?
|
| Infant Welfare | 1 | 2008 | 82 | 0.320 |
Why?
|
| Ovary | 3 | 2010 | 981 | 0.310 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2008 | 134 | 0.310 |
Why?
|
| Weight Gain | 4 | 2012 | 2282 | 0.300 |
Why?
|
| Boston | 12 | 2019 | 9305 | 0.300 |
Why?
|
| Spine | 5 | 2018 | 1143 | 0.290 |
Why?
|
| Cross-Sectional Studies | 23 | 2022 | 24913 | 0.290 |
Why?
|
| Anti-HIV Agents | 6 | 2018 | 4250 | 0.290 |
Why?
|
| Colitis, Ulcerative | 3 | 2014 | 1901 | 0.290 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2017 | 3760 | 0.290 |
Why?
|
| Societies, Medical | 6 | 2020 | 3740 | 0.280 |
Why?
|
| Prevalence | 12 | 2018 | 15194 | 0.280 |
Why?
|
| Gender Identity | 2 | 2022 | 681 | 0.280 |
Why?
|
| Respiratory Tract Infections | 1 | 2014 | 959 | 0.280 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2014 | 1210 | 0.280 |
Why?
|
| Case-Control Studies | 9 | 2022 | 21719 | 0.280 |
Why?
|
| Reproductive Medicine | 2 | 2018 | 108 | 0.280 |
Why?
|
| Women's Health | 2 | 2023 | 2034 | 0.270 |
Why?
|
| Social Justice | 2 | 2020 | 455 | 0.270 |
Why?
|
| Menstruation Disturbances | 3 | 2008 | 148 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 35342 | 0.270 |
Why?
|
| Fluorocarbons | 2 | 2022 | 452 | 0.270 |
Why?
|
| Pravastatin | 2 | 2019 | 395 | 0.270 |
Why?
|
| Cross-Cultural Comparison | 1 | 2009 | 651 | 0.270 |
Why?
|
| Risk Factors | 23 | 2020 | 72145 | 0.260 |
Why?
|
| Alanine Transaminase | 1 | 2008 | 592 | 0.260 |
Why?
|
| Pilot Projects | 6 | 2023 | 8297 | 0.250 |
Why?
|
| Child Development | 2 | 2014 | 2222 | 0.250 |
Why?
|
| Musculoskeletal System | 1 | 2007 | 175 | 0.250 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 2838 | 0.250 |
Why?
|
| Biomedical Research | 3 | 2011 | 3306 | 0.240 |
Why?
|
| Periodontal Diseases | 1 | 2008 | 449 | 0.240 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 15108 | 0.240 |
Why?
|
| Child Welfare | 1 | 2008 | 523 | 0.240 |
Why?
|
| Statistics, Nonparametric | 4 | 2011 | 2885 | 0.230 |
Why?
|
| Piperidines | 3 | 2019 | 1602 | 0.230 |
Why?
|
| Ultrasonography | 6 | 2007 | 5978 | 0.230 |
Why?
|
| Estradiol | 5 | 2023 | 2021 | 0.230 |
Why?
|
| Mandible | 1 | 2008 | 740 | 0.220 |
Why?
|
| Sex Characteristics | 2 | 2013 | 2585 | 0.220 |
Why?
|
| Contraceptives, Oral, Hormonal | 3 | 2012 | 188 | 0.220 |
Why?
|
| Radiography | 6 | 2012 | 7010 | 0.220 |
Why?
|
| Drug Administration Schedule | 5 | 2015 | 4929 | 0.210 |
Why?
|
| Oral Health | 1 | 2008 | 472 | 0.210 |
Why?
|
| Drug Therapy, Combination | 5 | 2016 | 6483 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3130 | 0.210 |
Why?
|
| Osteogenesis | 3 | 2006 | 1299 | 0.210 |
Why?
|
| Reference Values | 5 | 2014 | 4982 | 0.210 |
Why?
|
| Sports | 3 | 2007 | 686 | 0.200 |
Why?
|
| Infant, Newborn | 10 | 2022 | 25575 | 0.200 |
Why?
|
| Physicians | 1 | 2020 | 4554 | 0.200 |
Why?
|
| Osteoporotic Fractures | 3 | 2017 | 403 | 0.200 |
Why?
|
| Phthalic Acids | 2 | 2023 | 436 | 0.200 |
Why?
|
| Dihydrotestosterone | 1 | 2001 | 188 | 0.200 |
Why?
|
| Nutritional Requirements | 3 | 2012 | 285 | 0.200 |
Why?
|
| Child Nutrition Disorders | 1 | 2003 | 149 | 0.200 |
Why?
|
| Sexual Behavior | 2 | 2003 | 2050 | 0.200 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2023 | 738 | 0.200 |
Why?
|
| Hypothyroidism | 2 | 1997 | 659 | 0.200 |
Why?
|
| Nutritional Physiological Phenomena | 3 | 2011 | 370 | 0.190 |
Why?
|
| Galactosemias | 2 | 2012 | 125 | 0.190 |
Why?
|
| Prospective Studies | 18 | 2019 | 53187 | 0.190 |
Why?
|
| Aminophenols | 1 | 2021 | 78 | 0.190 |
Why?
|
| Hospitals, Urban | 1 | 2022 | 499 | 0.190 |
Why?
|
| Age Factors | 10 | 2017 | 18355 | 0.190 |
Why?
|
| Pyridines | 3 | 2019 | 2818 | 0.180 |
Why?
|
| Pituitary-Adrenal System | 2 | 2000 | 553 | 0.180 |
Why?
|
| Regression Analysis | 4 | 2018 | 6452 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2015 | 10943 | 0.180 |
Why?
|
| Decanoic Acids | 1 | 2019 | 66 | 0.180 |
Why?
|
| Singapore | 1 | 2020 | 295 | 0.170 |
Why?
|
| Diet Therapy | 1 | 2020 | 154 | 0.170 |
Why?
|
| Osteocalcin | 3 | 2009 | 273 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2018 | 5425 | 0.170 |
Why?
|
| Retrospective Studies | 12 | 2022 | 77098 | 0.170 |
Why?
|
| Androgens | 3 | 2007 | 1271 | 0.170 |
Why?
|
| Caprylates | 1 | 2019 | 111 | 0.170 |
Why?
|
| Treatment Outcome | 14 | 2018 | 62966 | 0.170 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 12242 | 0.160 |
Why?
|
| Food | 2 | 2020 | 769 | 0.160 |
Why?
|
| Resistance Training | 1 | 2020 | 164 | 0.160 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2022 | 269 | 0.160 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2020 | 399 | 0.160 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 1998 | 10 | 0.160 |
Why?
|
| Adenine | 2 | 2014 | 936 | 0.160 |
Why?
|
| Cohort Studies | 13 | 2021 | 40450 | 0.160 |
Why?
|
| Body Height | 4 | 2020 | 1574 | 0.160 |
Why?
|
| HIV Infections | 8 | 2018 | 16678 | 0.160 |
Why?
|
| Motor Activity | 2 | 2011 | 2714 | 0.160 |
Why?
|
| Child Nutritional Physiological Phenomena | 2 | 2022 | 303 | 0.160 |
Why?
|
| Lamin Type A | 1 | 2019 | 190 | 0.160 |
Why?
|
| Mental Health | 2 | 2023 | 2997 | 0.160 |
Why?
|
| Diagnostic Errors | 2 | 2016 | 1255 | 0.160 |
Why?
|
| Fertility | 1 | 2003 | 770 | 0.160 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2012 | 2195 | 0.150 |
Why?
|
| Rhode Island | 1 | 2018 | 347 | 0.150 |
Why?
|
| Quinolones | 1 | 2021 | 366 | 0.150 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 55 | 0.150 |
Why?
|
| Overweight | 2 | 2022 | 2366 | 0.150 |
Why?
|
| Endocrine System Diseases | 3 | 2011 | 248 | 0.150 |
Why?
|
| Skin Pigmentation | 2 | 2017 | 281 | 0.150 |
Why?
|
| Triglycerides | 3 | 2022 | 2450 | 0.150 |
Why?
|
| Motivation | 2 | 2005 | 1968 | 0.150 |
Why?
|
| Body Weight | 4 | 2014 | 4664 | 0.150 |
Why?
|
| Alkanesulfonic Acids | 1 | 2019 | 180 | 0.150 |
Why?
|
| Histamine H2 Antagonists | 1 | 2018 | 165 | 0.150 |
Why?
|
| Energy Intake | 4 | 2016 | 2147 | 0.150 |
Why?
|
| Seasons | 4 | 2017 | 1492 | 0.140 |
Why?
|
| Ohio | 1 | 2017 | 337 | 0.140 |
Why?
|
| Tomography, Emission-Computed | 1 | 2000 | 1144 | 0.140 |
Why?
|
| Weight-Bearing | 2 | 2011 | 514 | 0.140 |
Why?
|
| Life Style | 5 | 2017 | 3824 | 0.140 |
Why?
|
| Contraception Behavior | 1 | 2018 | 184 | 0.140 |
Why?
|
| Exercise Therapy | 2 | 2014 | 904 | 0.140 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2016 | 76 | 0.140 |
Why?
|
| Creatinine | 2 | 2019 | 1916 | 0.140 |
Why?
|
| Parenteral Nutrition | 2 | 2011 | 650 | 0.140 |
Why?
|
| Feeding Behavior | 3 | 2007 | 3187 | 0.140 |
Why?
|
| Water | 1 | 2022 | 1388 | 0.130 |
Why?
|
| Skin Care | 1 | 1995 | 49 | 0.130 |
Why?
|
| Neoplasms | 3 | 2023 | 21596 | 0.130 |
Why?
|
| Growth | 1 | 2017 | 376 | 0.130 |
Why?
|
| Povidone-Iodine | 1 | 1995 | 59 | 0.130 |
Why?
|
| Calcitriol | 2 | 2015 | 298 | 0.130 |
Why?
|
| Puberty, Precocious | 1 | 1997 | 155 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 2 | 2014 | 1017 | 0.130 |
Why?
|
| Waist Circumference | 1 | 2019 | 917 | 0.130 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 135 | 0.130 |
Why?
|
| Uterine Hemorrhage | 1 | 1997 | 255 | 0.130 |
Why?
|
| Maternal-Child Health Centers | 1 | 2015 | 40 | 0.130 |
Why?
|
| Education, Public Health Professional | 1 | 2015 | 24 | 0.130 |
Why?
|
| Follow-Up Studies | 7 | 2016 | 39004 | 0.130 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 5519 | 0.130 |
Why?
|
| Chronic Disease | 4 | 2014 | 9144 | 0.130 |
Why?
|
| Parietal Lobe | 1 | 2000 | 837 | 0.130 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2015 | 117 | 0.120 |
Why?
|
| Age Determination by Skeleton | 2 | 2014 | 129 | 0.120 |
Why?
|
| Accidental Falls | 2 | 2020 | 1057 | 0.120 |
Why?
|
| Patient Compliance | 3 | 2012 | 2680 | 0.120 |
Why?
|
| Hyperparathyroidism | 2 | 2015 | 339 | 0.120 |
Why?
|
| 25-Hydroxyvitamin D 2 | 2 | 2012 | 39 | 0.120 |
Why?
|
| Severity of Illness Index | 8 | 2017 | 15530 | 0.120 |
Why?
|
| Primary Health Care | 2 | 2008 | 4551 | 0.120 |
Why?
|
| Citrulline | 1 | 2014 | 105 | 0.120 |
Why?
|
| Sunlight | 1 | 2016 | 325 | 0.120 |
Why?
|
| Child, Hospitalized | 1 | 2016 | 174 | 0.120 |
Why?
|
| Scopolamine | 1 | 2014 | 99 | 0.120 |
Why?
|
| Interleukin-6 | 2 | 2014 | 3199 | 0.120 |
Why?
|
| Evidence-Based Medicine | 3 | 2017 | 3611 | 0.120 |
Why?
|
| Societies, Scientific | 2 | 2012 | 220 | 0.120 |
Why?
|
| Adjuvants, Immunologic | 2 | 2013 | 1000 | 0.120 |
Why?
|
| Health Behavior | 2 | 2005 | 2630 | 0.120 |
Why?
|
| Faith Healing | 1 | 2013 | 27 | 0.120 |
Why?
|
| Hip Fractures | 1 | 2022 | 954 | 0.110 |
Why?
|
| Radiotherapy | 2 | 2011 | 1525 | 0.110 |
Why?
|
| Cholesterol, HDL | 2 | 2022 | 1813 | 0.110 |
Why?
|
| Hyponatremia | 1 | 2016 | 298 | 0.110 |
Why?
|
| Risk-Taking | 1 | 1999 | 986 | 0.110 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2014 | 615 | 0.110 |
Why?
|
| Anti-Infective Agents, Local | 1 | 1995 | 250 | 0.110 |
Why?
|
| Massage | 1 | 2013 | 85 | 0.110 |
Why?
|
| Patient Selection | 4 | 2014 | 4214 | 0.110 |
Why?
|
| Mucositis | 1 | 2014 | 101 | 0.110 |
Why?
|
| Early Diagnosis | 2 | 2015 | 1184 | 0.110 |
Why?
|
| Dexamethasone | 1 | 2000 | 1949 | 0.110 |
Why?
|
| Proton Pump Inhibitors | 1 | 2018 | 521 | 0.110 |
Why?
|
| Endocrinology | 2 | 2017 | 443 | 0.110 |
Why?
|
| Cholinergic Antagonists | 1 | 2014 | 165 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2017 | 20086 | 0.110 |
Why?
|
| Bone Diseases, Developmental | 1 | 2013 | 130 | 0.110 |
Why?
|
| Hypophosphatemia | 1 | 2013 | 85 | 0.110 |
Why?
|
| Administration, Cutaneous | 2 | 2010 | 711 | 0.110 |
Why?
|
| Farnesyltranstransferase | 1 | 2012 | 76 | 0.110 |
Why?
|
| Nutrition Surveys | 2 | 2022 | 1656 | 0.110 |
Why?
|
| China | 2 | 2009 | 2246 | 0.110 |
Why?
|
| Drug Combinations | 1 | 2018 | 1961 | 0.110 |
Why?
|
| Hydrocortisone | 1 | 2000 | 1825 | 0.110 |
Why?
|
| Homosexuality, Male | 2 | 2018 | 1238 | 0.110 |
Why?
|
| Critical Illness | 3 | 2015 | 2665 | 0.110 |
Why?
|
| Choice Behavior | 1 | 2018 | 802 | 0.110 |
Why?
|
| Teriparatide | 1 | 2014 | 225 | 0.110 |
Why?
|
| Hypertriglyceridemia | 1 | 2015 | 293 | 0.100 |
Why?
|
| Liver | 1 | 2008 | 7470 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 7645 | 0.100 |
Why?
|
| Temporal Lobe | 1 | 2000 | 1669 | 0.100 |
Why?
|
| Relaxation Therapy | 1 | 2013 | 178 | 0.100 |
Why?
|
| Aging | 3 | 2013 | 8626 | 0.100 |
Why?
|
| Sunscreening Agents | 1 | 2012 | 132 | 0.100 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2012 | 126 | 0.100 |
Why?
|
| Body Fluid Compartments | 1 | 2011 | 52 | 0.100 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2013 | 113 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2016 | 764 | 0.100 |
Why?
|
| Cryptorchidism | 1 | 2012 | 123 | 0.100 |
Why?
|
| Patient Education as Topic | 2 | 2012 | 2275 | 0.100 |
Why?
|
| United States | 16 | 2021 | 69693 | 0.100 |
Why?
|
| Genetic Counseling | 1 | 2015 | 600 | 0.100 |
Why?
|
| Glucose Tolerance Test | 3 | 2017 | 1150 | 0.100 |
Why?
|
| Professional Competence | 1 | 2015 | 448 | 0.100 |
Why?
|
| Sex Education | 1 | 2012 | 93 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2014 | 3336 | 0.100 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 434 | 0.100 |
Why?
|
| Transplantation Conditioning | 1 | 2018 | 1597 | 0.100 |
Why?
|
| Health Status Disparities | 2 | 2020 | 1794 | 0.100 |
Why?
|
| Lipids | 1 | 2022 | 3302 | 0.100 |
Why?
|
| Fibroblast Growth Factors | 2 | 2014 | 879 | 0.100 |
Why?
|
| Homeostasis | 2 | 2012 | 3335 | 0.100 |
Why?
|
| Blood Sedimentation | 1 | 2011 | 231 | 0.100 |
Why?
|
| Medication Adherence | 2 | 2012 | 2055 | 0.100 |
Why?
|
| Urban Health Services | 1 | 2011 | 179 | 0.090 |
Why?
|
| Fertilization in Vitro | 1 | 2018 | 1284 | 0.090 |
Why?
|
| Risk Assessment | 6 | 2017 | 23320 | 0.090 |
Why?
|
| Blood Glucose | 3 | 2022 | 6249 | 0.090 |
Why?
|
| Diet | 4 | 2017 | 7923 | 0.090 |
Why?
|
| Patient Satisfaction | 2 | 2013 | 3391 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 8829 | 0.090 |
Why?
|
| Eating | 2 | 2007 | 1535 | 0.090 |
Why?
|
| Minerals | 1 | 2011 | 275 | 0.090 |
Why?
|
| Imidazoles | 1 | 2016 | 1205 | 0.090 |
Why?
|
| Sex Distribution | 2 | 2006 | 2295 | 0.090 |
Why?
|
| Beverages | 1 | 2015 | 820 | 0.090 |
Why?
|
| Administration, Intranasal | 1 | 2011 | 446 | 0.090 |
Why?
|
| Mentors | 1 | 2015 | 630 | 0.090 |
Why?
|
| Wrist Joint | 1 | 2011 | 256 | 0.090 |
Why?
|
| Gestational Age | 1 | 2018 | 3490 | 0.090 |
Why?
|
| History, 20th Century | 2 | 2018 | 2739 | 0.090 |
Why?
|
| Logistic Models | 4 | 2018 | 13403 | 0.090 |
Why?
|
| Growth Plate | 1 | 2011 | 274 | 0.090 |
Why?
|
| Energy Metabolism | 2 | 2011 | 2896 | 0.090 |
Why?
|
| Hirsutism | 2 | 1999 | 69 | 0.090 |
Why?
|
| Ultraviolet Rays | 1 | 2014 | 1059 | 0.090 |
Why?
|
| Muscular Diseases | 1 | 2013 | 557 | 0.080 |
Why?
|
| Organizational Policy | 1 | 2011 | 427 | 0.080 |
Why?
|
| Pregnancy | 4 | 2022 | 29087 | 0.080 |
Why?
|
| Vomiting | 2 | 2012 | 632 | 0.080 |
Why?
|
| Infant Formula | 1 | 2010 | 199 | 0.080 |
Why?
|
| Environmental Exposure | 2 | 2023 | 4231 | 0.080 |
Why?
|
| Growth Disorders | 1 | 2013 | 643 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2006 | 10163 | 0.080 |
Why?
|
| Endocrine Disruptors | 1 | 2011 | 237 | 0.080 |
Why?
|
| DMF Index | 1 | 2008 | 90 | 0.080 |
Why?
|
| Osteolysis | 1 | 2010 | 270 | 0.080 |
Why?
|
| Immobilization | 1 | 2009 | 236 | 0.080 |
Why?
|
| Radiography, Panoramic | 1 | 2008 | 115 | 0.080 |
Why?
|
| Immunoglobulin E | 1 | 2014 | 1460 | 0.080 |
Why?
|
| Periodontal Index | 1 | 2008 | 146 | 0.080 |
Why?
|
| Reproduction | 1 | 2012 | 668 | 0.080 |
Why?
|
| Ovarian Function Tests | 1 | 2007 | 11 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 4 | 2016 | 7276 | 0.080 |
Why?
|
| Steroid 21-Hydroxylase | 1 | 2007 | 34 | 0.070 |
Why?
|
| Time Factors | 7 | 2015 | 40054 | 0.070 |
Why?
|
| Incidence | 4 | 2018 | 20928 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2010 | 12958 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2017 | 6608 | 0.070 |
Why?
|
| Cost Savings | 1 | 2012 | 925 | 0.070 |
Why?
|
| Wrist | 1 | 2008 | 225 | 0.070 |
Why?
|
| Caffeine | 1 | 2011 | 699 | 0.070 |
Why?
|
| Phenotype | 2 | 2022 | 16331 | 0.070 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2007 | 139 | 0.070 |
Why?
|
| Middle Aged | 15 | 2021 | 213127 | 0.070 |
Why?
|
| Schools | 1 | 2014 | 1425 | 0.070 |
Why?
|
| Rheumatic Diseases | 2 | 2017 | 590 | 0.070 |
Why?
|
| Cholesterol | 2 | 2022 | 2895 | 0.070 |
Why?
|
| Saliva | 1 | 2010 | 805 | 0.070 |
Why?
|
| Drug Utilization | 1 | 2012 | 1181 | 0.070 |
Why?
|
| Communicable Diseases | 1 | 2014 | 878 | 0.070 |
Why?
|
| Cytokines | 3 | 2006 | 7317 | 0.070 |
Why?
|
| Guidelines as Topic | 2 | 2012 | 1402 | 0.070 |
Why?
|
| Progesterone | 1 | 2010 | 773 | 0.070 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2012 | 979 | 0.070 |
Why?
|
| Artifacts | 1 | 2014 | 1903 | 0.070 |
Why?
|
| Family | 2 | 2017 | 3144 | 0.070 |
Why?
|
| Longitudinal Studies | 5 | 2022 | 13921 | 0.070 |
Why?
|
| Patient Advocacy | 1 | 2008 | 353 | 0.070 |
Why?
|
| Leadership | 1 | 2015 | 1357 | 0.070 |
Why?
|
| Hypersensitivity | 1 | 2014 | 1093 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 3151 | 0.060 |
Why?
|
| Europe | 2 | 2011 | 3339 | 0.060 |
Why?
|
| Carbonated Beverages | 1 | 2006 | 214 | 0.060 |
Why?
|
| Risk | 4 | 2016 | 9679 | 0.060 |
Why?
|
| Rest | 1 | 2010 | 900 | 0.060 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 950 | 0.060 |
Why?
|
| Milk | 1 | 2007 | 449 | 0.060 |
Why?
|
| Sample Size | 1 | 2008 | 844 | 0.060 |
Why?
|
| Age of Onset | 1 | 2011 | 3266 | 0.060 |
Why?
|
| Equipment Design | 1 | 2013 | 3582 | 0.060 |
Why?
|
| Insulin Resistance | 3 | 2017 | 3861 | 0.060 |
Why?
|
| Brain Mapping | 1 | 2020 | 6669 | 0.060 |
Why?
|
| Drug Costs | 1 | 2012 | 1104 | 0.060 |
Why?
|
| Cost of Illness | 2 | 2012 | 1852 | 0.060 |
Why?
|
| Contraceptives, Oral | 1 | 2006 | 563 | 0.060 |
Why?
|
| Brain | 2 | 2020 | 26343 | 0.060 |
Why?
|
| Counseling | 1 | 2012 | 1521 | 0.060 |
Why?
|
| Linear Models | 3 | 2016 | 5948 | 0.060 |
Why?
|
| Urban Health | 1 | 2006 | 547 | 0.060 |
Why?
|
| Mass Screening | 2 | 2014 | 5238 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2009 | 15056 | 0.060 |
Why?
|
| Respiratory Function Tests | 1 | 2007 | 1613 | 0.060 |
Why?
|
| Musculoskeletal Diseases | 1 | 2009 | 581 | 0.060 |
Why?
|
| Health Planning Guidelines | 1 | 2004 | 163 | 0.060 |
Why?
|
| Nutrition Assessment | 1 | 2006 | 723 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2010 | 3001 | 0.060 |
Why?
|
| Knee Joint | 1 | 2011 | 1679 | 0.050 |
Why?
|
| Causality | 1 | 2009 | 1265 | 0.050 |
Why?
|
| Athletes | 1 | 2010 | 1092 | 0.050 |
Why?
|
| Hyperandrogenism | 1 | 2002 | 38 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 2010 | 2027 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2011 | 1636 | 0.050 |
Why?
|
| Diet Surveys | 1 | 2006 | 1172 | 0.050 |
Why?
|
| Aged | 8 | 2021 | 162944 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 3766 | 0.050 |
Why?
|
| Periodicals as Topic | 1 | 2013 | 1431 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 4554 | 0.050 |
Why?
|
| Pain | 2 | 2016 | 4961 | 0.050 |
Why?
|
| Sex Factors | 3 | 2015 | 10392 | 0.050 |
Why?
|
| Parents | 1 | 2015 | 3387 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 2951 | 0.050 |
Why?
|
| Gene Transfer Techniques | 1 | 2007 | 1224 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 3800 | 0.050 |
Why?
|
| Sympathetic Nervous System | 1 | 2004 | 514 | 0.050 |
Why?
|
| Public Health Practice | 1 | 2004 | 217 | 0.050 |
Why?
|
| Probability | 1 | 2007 | 2502 | 0.050 |
Why?
|
| Survivors | 1 | 2011 | 2286 | 0.050 |
Why?
|
| Animals | 8 | 2012 | 168561 | 0.050 |
Why?
|
| Athletic Injuries | 1 | 2011 | 1153 | 0.050 |
Why?
|
| Depression | 1 | 2000 | 7733 | 0.050 |
Why?
|
| Snoring | 1 | 2022 | 189 | 0.050 |
Why?
|
| Metformin | 1 | 2007 | 829 | 0.050 |
Why?
|
| Focus Groups | 1 | 2005 | 1320 | 0.050 |
Why?
|
| Hospitalization | 2 | 2010 | 10232 | 0.040 |
Why?
|
| Carotid Arteries | 2 | 2016 | 952 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8328 | 0.040 |
Why?
|
| Nutrition Disorders | 1 | 2000 | 211 | 0.040 |
Why?
|
| Internet | 1 | 2012 | 3062 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2002 | 592 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2014 | 4030 | 0.040 |
Why?
|
| Heart Rate | 2 | 2001 | 4091 | 0.040 |
Why?
|
| Mental Disorders | 1 | 1999 | 6587 | 0.040 |
Why?
|
| Adrenal Glands | 1 | 2001 | 547 | 0.040 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 4566 | 0.040 |
Why?
|
| HIV | 2 | 2018 | 1600 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 170 | 0.040 |
Why?
|
| Androgen Antagonists | 1 | 2007 | 1350 | 0.040 |
Why?
|
| Research Subjects | 1 | 2020 | 238 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2004 | 1163 | 0.040 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2000 | 648 | 0.040 |
Why?
|
| Health Status | 2 | 2015 | 4030 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2004 | 1239 | 0.040 |
Why?
|
| Self Report | 2 | 2022 | 3548 | 0.040 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2021 | 437 | 0.040 |
Why?
|
| Body Image | 1 | 2002 | 609 | 0.040 |
Why?
|
| Glucose Intolerance | 1 | 2002 | 577 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 2 | 2016 | 2167 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 1998 | 803 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2007 | 3420 | 0.040 |
Why?
|
| Heart | 1 | 2010 | 4462 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2020 | 358 | 0.040 |
Why?
|
| Condoms | 1 | 1999 | 323 | 0.040 |
Why?
|
| Thrombosis | 1 | 2011 | 2966 | 0.040 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 1997 | 53 | 0.040 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 1997 | 101 | 0.040 |
Why?
|
| Protein Prenylation | 1 | 2016 | 73 | 0.040 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 2016 | 16 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2000 | 711 | 0.040 |
Why?
|
| Ovulation Induction | 1 | 2018 | 274 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 7901 | 0.030 |
Why?
|
| Hypertension | 1 | 2016 | 8455 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2017 | 664 | 0.030 |
Why?
|
| Ovarian Cysts | 1 | 1997 | 115 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2018 | 1872 | 0.030 |
Why?
|
| Tongue Neoplasms | 1 | 1998 | 179 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2001 | 1353 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 1792 | 0.030 |
Why?
|
| Asthma | 1 | 2014 | 5955 | 0.030 |
Why?
|
| Pheochromocytoma | 1 | 1998 | 337 | 0.030 |
Why?
|
| Postmenopause | 2 | 2001 | 2461 | 0.030 |
Why?
|
| Bradycardia | 1 | 1997 | 305 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2007 | 2866 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2020 | 968 | 0.030 |
Why?
|
| Prolactin | 1 | 1997 | 669 | 0.030 |
Why?
|
| Disease Progression | 2 | 2011 | 13256 | 0.030 |
Why?
|
| Interdisciplinary Studies | 1 | 2015 | 89 | 0.030 |
Why?
|
| Sexual Partners | 1 | 1999 | 730 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 5133 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2022 | 2303 | 0.030 |
Why?
|
| Inflammation | 1 | 2014 | 10578 | 0.030 |
Why?
|
| Collagen | 1 | 2002 | 2684 | 0.030 |
Why?
|
| Attitude | 1 | 1999 | 772 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2001 | 2513 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2003 | 2051 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 1999 | 949 | 0.030 |
Why?
|
| Calibration | 1 | 2016 | 815 | 0.030 |
Why?
|
| Dietary Sucrose | 1 | 2015 | 247 | 0.030 |
Why?
|
| Ethylene Glycols | 1 | 2014 | 156 | 0.030 |
Why?
|
| Placebos | 1 | 2018 | 1677 | 0.030 |
Why?
|
| Thyroxine | 1 | 1997 | 666 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2003 | 1617 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 168 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 7988 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 20774 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2000 | 2290 | 0.030 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2013 | 129 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 2354 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 1533 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1998 | 740 | 0.030 |
Why?
|
| Maze Learning | 1 | 2014 | 478 | 0.030 |
Why?
|
| Inhibins | 1 | 2012 | 211 | 0.030 |
Why?
|
| Sperm Count | 1 | 2012 | 216 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2004 | 2068 | 0.030 |
Why?
|
| Perception | 1 | 2018 | 1188 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 2130 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 14720 | 0.030 |
Why?
|
| Marital Status | 1 | 2013 | 437 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2021 | 2556 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 1999 | 1423 | 0.020 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2011 | 68 | 0.020 |
Why?
|
| Health Policy | 1 | 2004 | 2657 | 0.020 |
Why?
|
| Progesterone Congeners | 1 | 2011 | 42 | 0.020 |
Why?
|
| Stroke | 1 | 2014 | 9963 | 0.020 |
Why?
|
| Drainage | 1 | 1997 | 1140 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 7770 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2001 | 2732 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 802 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2015 | 754 | 0.020 |
Why?
|
| Research Report | 1 | 2013 | 355 | 0.020 |
Why?
|
| Peptides | 1 | 2002 | 4392 | 0.020 |
Why?
|
| Semen | 1 | 2012 | 316 | 0.020 |
Why?
|
| Pedigree | 1 | 1998 | 4646 | 0.020 |
Why?
|
| Phosphates | 1 | 2013 | 786 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2018 | 2680 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 2010 | 330 | 0.020 |
Why?
|
| Calorimetry, Indirect | 1 | 2010 | 183 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2015 | 1459 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 12344 | 0.020 |
Why?
|
| Social Support | 1 | 1999 | 2117 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 1995 | 778 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2014 | 983 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 2014 | 565 | 0.020 |
Why?
|
| Program Development | 1 | 2015 | 1314 | 0.020 |
Why?
|
| Lung | 1 | 2007 | 9826 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 6171 | 0.020 |
Why?
|
| Documentation | 1 | 2014 | 865 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2014 | 1520 | 0.020 |
Why?
|
| Cell Line | 1 | 2001 | 15994 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2014 | 1106 | 0.020 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2007 | 222 | 0.020 |
Why?
|
| Neonatal Screening | 1 | 2011 | 591 | 0.020 |
Why?
|
| Algorithms | 1 | 2007 | 13853 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2014 | 1548 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 13655 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2015 | 1760 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2016 | 2041 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2015 | 2485 | 0.020 |
Why?
|
| Health Surveys | 1 | 2016 | 4030 | 0.020 |
Why?
|
| Sleep | 1 | 2022 | 4604 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2001 | 19223 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 2451 | 0.020 |
Why?
|
| Insulin | 1 | 2000 | 6575 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 1343 | 0.020 |
Why?
|
| Gymnastics | 1 | 2005 | 26 | 0.020 |
Why?
|
| Educational Status | 1 | 2013 | 2533 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 1526 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 6365 | 0.020 |
Why?
|
| Communication | 1 | 1999 | 3728 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2001 | 5705 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5062 | 0.020 |
Why?
|
| Social Marketing | 1 | 2004 | 51 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 2211 | 0.020 |
Why?
|
| Sheep | 1 | 2007 | 1437 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 19862 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2010 | 2372 | 0.010 |
Why?
|
| Canada | 1 | 2009 | 2061 | 0.010 |
Why?
|
| Fetus | 1 | 2011 | 1879 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2010 | 814 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 6030 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3862 | 0.010 |
Why?
|
| Tobacco Industry | 1 | 2004 | 126 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2007 | 1547 | 0.010 |
Why?
|
| Federal Government | 1 | 2004 | 260 | 0.010 |
Why?
|
| Public Sector | 1 | 2004 | 264 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2006 | 607 | 0.010 |
Why?
|
| Neurodegenerative Diseases | 1 | 2011 | 1060 | 0.010 |
Why?
|
| Length of Stay | 1 | 2015 | 6294 | 0.010 |
Why?
|
| Testosterone | 1 | 2012 | 2401 | 0.010 |
Why?
|
| Aspirin | 1 | 2014 | 3278 | 0.010 |
Why?
|
| Comorbidity | 1 | 2016 | 10372 | 0.010 |
Why?
|
| Taxes | 1 | 2004 | 221 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2015 | 5310 | 0.010 |
Why?
|
| Health Personnel | 1 | 2015 | 3210 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2010 | 1167 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 3067 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 6974 | 0.010 |
Why?
|
| Kidney | 1 | 2016 | 7167 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2014 | 10248 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2016 | 3738 | 0.010 |
Why?
|
| Private Sector | 1 | 2004 | 390 | 0.010 |
Why?
|
| Running | 1 | 2005 | 478 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2010 | 4197 | 0.010 |
Why?
|
| Health Promotion | 1 | 2012 | 2194 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 2900 | 0.010 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2011 | 2407 | 0.010 |
Why?
|
| Public Health | 1 | 2011 | 2594 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 3770 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 6259 | 0.010 |
Why?
|
| Adolescent Medicine | 1 | 1998 | 72 | 0.010 |
Why?
|
| Genotype | 1 | 2011 | 12946 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2001 | 57683 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2007 | 1884 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1999 | 11695 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 9581 | 0.010 |
Why?
|
| Research Design | 1 | 2010 | 5979 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 7790 | 0.010 |
Why?
|
| Cause of Death | 1 | 2004 | 3571 | 0.010 |
Why?
|
| Prognosis | 1 | 2014 | 29010 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2005 | 9846 | 0.010 |
Why?
|
| Outpatients | 1 | 1999 | 1483 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 17400 | 0.010 |
Why?
|
| Smoking | 1 | 2004 | 8969 | 0.000 |
Why?
|
| Referral and Consultation | 1 | 1999 | 3527 | 0.000 |
Why?
|